TRANSFORMING PHARMA WITH SYNTHETIC BIOLOGY
Our Products
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Pipeline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Product
Proof of concept
R&D
Pilot
API validation
On market
Our focus
Platform Technologies
Integrating Synthetic Biology with Traditional Chemistry
Our Hybrid Platform is Solving Industry Challenges
Traditional methods of producing alkaloid APIs are complex, environmentally challenging and expensive.
River Stone Biotech’s manufacturing and process development capabilities couple fermentation with improved chemistry methodology. This combination approach enables flexible intermediates to be taken into more streamlined chemistry conversion processes, driving efficiencies across many criteria.
The result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.
A Spotlight on Substance Use Disorders
Priority Market
Our priority focus is on the very expensive APIs buprenorphine, naloxone and naltrexone – used in treatments for opioid use disorder, alcohol use disorder, opioid overdose and pain. In line with high prevalence of these indications, we expect an increasing need for production of these life-changing APIs.
Publications & Presentation
View our select investor presentations and scientific publications for the latest information and updates
News
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
$6.8M Series B Financing to Advance Lead Pipeline Projects
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing.
River Stone Biotech Inc. participates in DCAT 2022 conference
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing.
U.S. PATENT TO PROTECT BUPRENORPHINE PRODUCTION PROCESS
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing.
RIVER STONE AWARDED KEY US PATENT
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing.
News
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
$6.8M Series B Financing to Advance Lead Pipeline Projects
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating...
River Stone Biotech Inc. participates in DCAT 2022 conference
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating...
U.S. Patent to protect Buprenorphine production process
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating...
River Stone awarded key US patent
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating
Pipeline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Product
Proof of concept
R&D
Pilot
API validation
On market
Pipeline
Følg med vores nuværende produktion af…
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Products
Proof of concept
R&D
Pilot
API validation
On market
Any questions?
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.